shortage of glp-1 receptor agonists Agonist Market Size & Trends 2035 Exploring the Side Effects of
Description
Reduction of Major Cardiovascular Events The SELECT trial of semaglutide (vs placebo) will be presented in November at the American Heart Association
February 26, 2024
GLP-1 and glucagon co-agonists Glucagon is secreted from the pancreatic a-cells and the main physiological site of action is the liver to increase hepatic glucose production [60]
Long-acting ones (liraglutide, dulaglutide, exenatide weekly, semaglutide) keep working for at least 24 hours [2]
Goldberg M, Gomez-Orellana I
